Your browser doesn't support javascript.
loading
The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.
Augusto, João B; Johner, Nicolas; Shah, Dipen; Nordin, Sabrina; Knott, Kristopher D; Rosmini, Stefania; Lau, Clement; Alfarih, Mashael; Hughes, Rebecca; Seraphim, Andreas; Vijapurapu, Ravi; Bhuva, Anish; Lin, Linda; Ojrzynska, Natalia; Geberhiwot, Tarekegn; Captur, Gabriella; Ramaswami, Uma; Steeds, Richard P; Kozor, Rebecca; Hughes, Derralynn; Moon, James C; Namdar, Mehdi.
Afiliação
  • Augusto JB; Institute of Cardiovascular Science, University College London, London, UK.
  • Johner N; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Shah D; Cardiology Division, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland.
  • Nordin S; Cardiology Division, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva, Switzerland.
  • Knott KD; Institute of Cardiovascular Science, University College London, London, UK.
  • Rosmini S; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Lau C; Institute of Cardiovascular Science, University College London, London, UK.
  • Alfarih M; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Hughes R; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Seraphim A; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Vijapurapu R; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK.
  • Bhuva A; Institute of Cardiovascular Science, University College London, London, UK.
  • Lin L; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Ojrzynska N; Institute of Cardiovascular Science, University College London, London, UK.
  • Geberhiwot T; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Captur G; Institute of Cardiovascular Science, University College London, London, UK.
  • Ramaswami U; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Steeds RP; Cardiology Department, University Hospitals Birmingham, Birmingham, UK.
  • Kozor R; Institute of Cardiovascular Science, University College London, London, UK.
  • Hughes D; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Moon JC; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
  • Namdar M; Department of Cardiovascular Imaging, Barts Heart Centre, Barts Health NHS Trust, London, UK.
Eur Heart J Cardiovasc Imaging ; 22(7): 790-799, 2021 06 22.
Article em En | MEDLINE | ID: mdl-32514567
AIMS: Cardiac involvement in Fabry disease (FD) occurs prior to left ventricular hypertrophy (LVH) and is characterized by low myocardial native T1 with sphingolipid storage reflected by cardiovascular magnetic resonance (CMR) and electrocardiogram (ECG) changes. We hypothesize that a pre-storage myocardial phenotype might occur even earlier, prior to T1 lowering. METHODS AND RESULTS: FD patients and age-, sex-, and heart rate-matched healthy controls underwent same-day ECG with advanced analysis and multiparametric CMR [cines, global longitudinal strain (GLS), T1 and T2 mapping, stress perfusion (myocardial blood flow, MBF), and late gadolinium enhancement (LGE)]. One hundred and fourteen Fabry patients (46 ± 13 years, 61% female) and 76 controls (49 ± 15 years, 50% female) were included. In pre-LVH FD (n = 72, 63%), a low T1 (n = 32/72, 44%) was associated with a constellation of ECG and functional abnormalities compared to normal T1 FD patients and controls. However, pre-LVH FD with normal T1 (n = 40/72, 56%) also had abnormalities compared to controls: reduced GLS (-18 ± 2 vs. -20 ± 2%, P < 0.001), microvascular changes (lower MBF 2.5 ± 0.7 vs. 3.0 ± 0.8 mL/g/min, P = 0.028), subtle T2 elevation (50 ± 4 vs. 48 ± 2 ms, P = 0.027), and limited LGE (%LGE 0.3 ± 1.1 vs. 0%, P = 0.004). ECG abnormalities included shorter P-wave duration (88 ± 12 vs. 94 ± 15 ms, P = 0.010) and T-wave peak time (Tonset - Tpeak; 104 ± 28 vs. 115 ± 20 ms, P = 0.015), resulting in a more symmetric T wave with lower T-wave time ratio (Tonset - Tpeak)/(Tpeak - Tend) (1.5 ± 0.4 vs. 1.8 ± 0.4, P < 0.001) compared to controls. CONCLUSION: FD has a measurable myocardial phenotype pre-LVH and pre-detectable myocyte storage with microvascular dysfunction, subtly impaired GLS and altered atrial depolarization and ventricular repolarization intervals.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Fabry Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Eur Heart J Cardiovasc Imaging Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Fabry Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Eur Heart J Cardiovasc Imaging Ano de publicação: 2021 Tipo de documento: Article